Renhe Pharmacy released its 2026 interim report. During the reporting period, the company's total operating revenue was 2.091 billion yuan, and net profit attributable to the parent company was 292 million yuan. Net cash inflow from operating activities was 572 million yuan, a decrease of 99.0157 million yuan compared with the same period last year, down 14.75 percent year on year. The company's latest asset-liability ratio was 11.85 percent, and gross margin was 35.96 percent, ranking 35th among peer companies that have already disclosed results. Diluted earnings per share were 0.21 yuan, total asset turnover was 0.26 times, and inventory turnover was 3.17 times. The number of shareholders was 88,600, and the top ten shareholders held 34.09 percent of total share capital.
Renhe Pharmacy Co LtdInterim report shows net profit of 292 million yuan, indicating profitability.
